Table 3.
Detailed European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core questions 30 and Pancreatic Modification (28 questions) results in disease duration-matched patients with chronic pancreatitis
| Scales | Items | CP patients on Antox mean score (n = 28) | CP patients NOT on Antox mean score (n = 28) | P-value | 95% CI |
| Physical Functioning | Q-1-5 | 1.5 | 1.97 | 0.0051 | -0.8 to 0.1 |
| Role Functioning | Q-6-7 | 1.84 | 2.75 | 0.0011 | -1.5 to 0.5 |
| Pain | Q-9, 19 | 2.1 | 3.1 | < 0.00011 | -1.5 to 0.7 |
| Fatigue | Q-10, 12, 18 | 2.05 | 2.86 | 0.00011 | -1.7 to 0.3 |
| Nausea and vomiting | Q-14, 15 | 1.5 | 2.2 | 0.0021 | -1.2 to 0.2 |
| Cognitive functioning | Q-20, 25 | 1.6 | 2.4 | < 0.00011 | -1 to 0.5 |
| Emotional functioning | Q-21-24 | 1.8 | 2.6 | 0.00071 | -1.2 to 0.5 |
| Social functioning | Q-26, 27 | 1.8 | 2.7 | 0.00321 | -1.2 to 0.2 |
| Global quality of life | Q-29, 30 | 2.6 | 4.9 | < 0.00011 | 1.5 to 3 |
| Pancreatic Pain | Q-31, 33, 35 | 1.9 | 2.9 | < 0.00011 | -1.5 to -0.7 |
| Digestive function | Q-36, 37 | 2.14 | 2.5 | 0.091 | -1 to 0 |
| Jaundice | Q-44, 45 | 1.1 | 1.2 | 0.411 | -0.25 to 0 |
| Altered bowel functioning | Q-46, 47 | 2.1 | 1.6 | 0.071 | -1 to 0 |
| Body Image | Q-48, 51 | 1.3 | 2.5 | 0.00041 | -1.2 to -0.25 |
| Alcohol related guilt | Q-49, 50 | 1.5 | 1.4 | 0.71 | -0.25 to 0.5 |
| Satisfaction with health care | Q-55, 56 | 3.2 | 3.4 | 0.441 | -0.5 to 0.25 |
| Sexual functioning | Q-57, 58 | 1.7 | 2.66 | 0.00031 | -1.5 to -0.5 |
| Dyspnea/shortness of breath | Q-8 | 1.5 | 1.6 | 0.631 | -0.5 to 0 |
| Difficulty sleeping | Q-11 | 1.9 | 2.9 | 0.00031 | -1.5 to 0.5 |
| Loss of appetite | Q-13 | 1.8 | 2.5 | 0.041 | -1.5 to 0 |
| Constipation | Q-16 | 1.7 | 1.8 | 0.862 | -1 to 0.5 |
| Diarrhea | Q-17 | 1.5 | 1.5 | 0.032 | -1 to 0 |
| Financial problems | Q-28 | 1.3 | 1.9 | 0.022 | -1 to 0 |
| Bloated abdomen | Q-32 | 1.9 | 2.8 | 0.0022 | -1.5 to 0.5 |
| Night pain | Q-34 | 1.8 | 3.1 | < 0.00012 | -2 to -0.5 |
| Taste changes | Q-38 | 1.2 | 1.7 | 0.022 | -1 to 0 |
| Indigestion | Q-39 | 1.7 | 2.4 | 0.0182 | -1 to 0 |
| Flatulence | Q-40 | 2.0 | 2.6 | 0.062 | -1 to 0 |
| Weight loss | Q-41 | 1.2 | 2.4 | < 0.00012 | -1.5 to -0.5 |
| Decreased muscle strength | Q-42 | 1.8 | 2.3 | 0.112 | -1 to 0 |
| Dry mouth | Q-43 | 1.6 | 2.2 | 0.022 | -1 to 0 |
| Treatment side effects | Q-52 | 1.2 | 2.0 | 0.00022 | -1 to -0.5 |
| Fear for future health | Q-53 | 2.4 | 3.0 | 0.032 | -1 to 0 |
| Ability to plan ahead | Q-54 | 1.8 | 2.9 | 0.00012 | -1.5 to 0.5 |
1
Wilcoxon signed rank test 95% CI;
2
Wilcoxon t-test. CP: Chronic pancreatitis; Q: Question No. (total C-30 + PAN 28 = 58 questions).